

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: BioMark Diagnostics Inc. (the "Issuer").

Trading Symbol: BUX

Number of Outstanding Listed Securities: 77,974,229

Date: July 4, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Issuer continued its business of developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early, accurately and cost effectively.**

2. Provide a general overview and discussion of the activities of management.
  - **As COVID-19 pandemic management measures intensity with aggressive vaccination program being implemented there are hopeful signs that business activity might resume normally. The major caveat being the B17 variant which has high transmissibility. Financial, operational and recovery measures instituted by the management team aided in sustaining business viability over the past 12 months and the company intends to keep a vigilant eye should another wave erupt in the fall. Financial measures include reducing working capital, delaying capital expenditures(equipment), cost cutting initiatives and tapping into government grants/support programs.**
  - **On June 1, 2021, BioMark announced that its wholly owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") received funding to develop an early-stage lung cancer screening assay using BioMark's proprietary liquid biopsy platform. The total sponsored research grant is about \$825,000 and a major portion of the funding is being provided by the Consortium for Industrial Research and Innovation in Medical Technology (MEDTEQ+) and Spark grant from the Canadian Cancer Society (CCS, grant # 707073), the Canadian Institutes of Health Research – Institute of Cancer Research (CIHR-ICR, grant # 0590008438), and Brain Canada Foundation. This initiative entitled "A Pan Canadian initiative for the development of a liquid biopsy assay for lung cancer screening" is being led by Dr. Philippe Joubert and a team of leading clinicians, academic researchers, and data scientists.**
  - **BioMark presented Biotech Innovation Conference (Bio Conference) that was an online event with over 6000 companies from over 50**

**countries. The conference was held from June 10th to June 18th, 2021. BioMark is now engaged in preliminary discussions with several financial and bio-tech companies. BIO Digital virtually convened over 6,000 participants for several days of programming, networking, and BIO One-on-One Partnering to connect biotech innovators across the globe.**

- Breast cancer samples (over 250) were analysed at Dr. Wishart's TMIC located at University of Alberta. Detailed bioinformatics data analysis will be conducted during the months of July and Aug 2021.**
- Launch Online Grant Program was approved on June 14<sup>th</sup>, 2021. The purpose of this program, which was made possible through funding from the Province of British Columbia, is to support businesses to build an online shop or online booking system, make improvements to existing e-commerce functionality and/or booking systems, and to fund digital customer acquisition activities to respond to changing customer expectations and help gain access to local customers and markets otherwise out of reach. This program will be managed by Alacrity Canada.**
- On June 29, 2021, BioMark announced that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen With or Without Immunotherapy. Since immunotherapy is now standard of care for lung cancer, BioMark amended the protocol to include study participants receiving immunotherapy and added the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) as an additional site under the supervision of Dr Philippe Joubert. The amended protocol is intended to test the hypothesis that downregulation of SSAT1 activity as reflected by a reduced plasma concentration of acetylamantadine, will occur earlier than can be detected by other diagnostic testing methods used to determine the efficacy of chemotherapy combined or not to immunotherapy in patients with a diagnosis of stage III lung cancer. This amendment approval from Health Canada will facilitate the study and permit achieving the required sample size in a timely manner. Patient recruitment is anticipated to commence later in the 3<sup>rd</sup> quarter.**

- **Progressive developments in expansion of BioMark’s liquid biopsy assay is underway in several facilities. Additional cancer biopsy samples were shipped from CHTN - Collaborative Human Tissue Network based in USA and funded by NCI in late June to increase the statistical power of the discovery. Patents have been drafted and provisional filed upon further clinical validation activities. Mitacs grants have been secured to further accelerate the scientific activities associated to this research. The CHTN is a unique NCI supported resource that provides human tissues and fluids from routine procedures to investigators who utilize human biospecimens in their research. Unlike tissue banks, the CHTN works prospectively with each investigator to tailor specimen acquisition and processing to meet their specific project requirements. High quality biospecimens available from surgeries, autopsies and other routine procedures.**

#### **About Phytronix Technologies Inc.**

Phytronix Technologies Inc. is a privately-owned company based in Québec City, Canada, and was founded in 2000. Phytronix invented and patented the Laser Diode Thermal Desorption (LDTD) technology for mass spectrometry. The company introduced the Luxon Ion Source®, which is the second-generation apparatus based on the patented-LDTD® technology and currently the fastest technology for mass spectrometry. This innovative technology enables ultra-high-speed analysis in less than 4 seconds per sample. The company will provide the optimized internal standards that are necessary for use in clinical settings, along with technical expertise required with high-throughput mass spectrometry.

#### **About MEDTEQ+**

MEDTEQ+ ([www.medteq.ca](http://www.medteq.ca)) is the pan-Canadian Consortium for Industrial Research and Innovation in Medical Technology. Its mission is to accelerate the development of innovative technological solutions to improve patients' health and quality of life. MEDTEQ+ supports their validation and integration in the healthcare system and their impact, both locally and globally, by bringing together the complementary skills of industrial and academic partners, and with those of healthcare providers. MEDTEQ+ relies on the financial support of the Government of Quebec, the Government of Canada (delivered through the Centres of Excellence for Commercialization and Research (CECR)), the private sector and complementary partners to foster research-industry relations.

### **About Sparks Grant.**

The Canadian Cancer Society (CCS), the Canadian Institutes of Health Research - Institute of Cancer Research (CIHR-ICR), and Brain Canada Foundation (BC) have committed a total of \$150K for Novel Technology Applications in Cancer Prevention and Early Detection. Spark Grants will support the development of new partnerships and the exploration of highly novel concepts, involving researchers from any research area, and particularly from non-traditional cancer fields, such as engineering, AI, robotics, physics, nanoscience, statistics, informatics, computer and data sciences, behavioural science, and any other discipline poised to seed the next generation of disruptive technologies in cancer control. BioMark would like to thank all the supporting agencies for their support (CCS grant # 707073/CIHR-IRSC grant # 0590008438) will acknowledge them in publications or events related to the use of the funds.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Not applicable.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**Not applicable.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Not applicable.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Not applicable.**

---

## **FORM 7 – MONTHLY PROGRESS REPORT**

January 2015

Page 5

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**Not applicable.**

8. Describe the acquisition of new customers or loss of customers.

**Not applicable.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

**The Issuer continues to file trademark and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.**

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

**Not applicable.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**Not applicable.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**Not applicable.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**Not applicable.**

14. Provide details of any securities issued and options or warrants granted.

**Not applicable.**

---

## FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 6

15. Provide details of any loans to or by Related Persons.

**Not applicable.**

16. Provide details of any changes in directors, officers, or committee members.

**Not applicable.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The trends and risks which are likely to impact the Issuer are discussed in the Form 51-102F1 Management's Discussion & Analysis Annual Report for the Year Ended March 31, 2020.**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 4, 2021.

Rashid Ahmed Maula Bux  
Name of Director or Senior Officer

"Rashid Ahmed Maula Bux"  
Signature

President & CEO  
Official Capacity

<b>Issuer Details</b>	For Month End	Date of Report
Name of Issuer	June, 2021	YY/MM/DD
BioMark Diagnostics Inc.		2021/07/04
Issuer Address		
130 - 3851 Shell Road		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Richmond, BC, V6X 2W2	N/A	(604) 370-0779
Contact Name	Contact Position	Contact Telephone No.
Rashid Ahmed Bux	CEO	(604) 370-0779
Contact Email Address	Web Site Address	
<a href="mailto:info@biomarkdiagnostics.com">info@biomarkdiagnostics.com</a>	www.biomarkdiagnostics.com	

### FORM 7 – MONTHLY PROGRESS REPORT

January 2015